

# GW 501516

Catalog No: tcsc0438



## Available Sizes

**Size:** 5mg

**Size:** 10mg

**Size:** 50mg

**Size:** 100mg

**Size:** 200mg

**Size:** 500mg

**Size:** 1g



## Specifications

**CAS No:**

317318-70-0

**Formula:**

$C_{21}H_{18}F_3NO_3S_2$

**Pathway:**

Cell Cycle/DNA Damage;Autophagy

**Target:**

PPAR;Autophagy

**Purity / Grade:**

>98%

**Solubility:**

DMSO :  $\geq 100$  mg/mL (220.51 mM); H<sub>2</sub>O :

**Alternative Names:**

GW 1516;GSK-516

**Observed Molecular Weight:**

453.5


**Product Description**

GW 501516 is a **PPAR $\delta$**  agonist with an **EC<sub>50</sub>** of 1.1 nM.

IC50 & Target: EC50: 1.1 nM (PPAR $\delta$ )<sup>[1]</sup>

**In Vitro:** GW 501516 is shown to be the most potent and selective PPAR $\alpha$  agonists known with an EC<sub>50</sub> of 1.1 nM against PPAR $\alpha$  and 1000-fold selectivity over the other human subtypes, PPAR $\alpha$  and- $\gamma$ <sup>[1]</sup>. GW 501516 exerts anti-inflammatory effects in mouse cultured proximal tubular (mProx) cells. GW 501516 inhibits palmitate- and TNF $\alpha$ -induced increases in MCP-1 mRNA expression in a dose-dependent manner<sup>[3]</sup>.

**In Vivo:** GW 501516 causes impaired bone formation, leading to decreased BMD and deterioration of bone properties in OVX rats<sup>[2]</sup>. GW 501516 attenuates interstitial inflammation and proximal tubular cell damage in a protein-overload mouse nephropathy model<sup>[3]</sup>. GW 501516 treatment enhances running endurance and the proportion of succinate dehydrogenase (SDH)-positive muscle fibres in both trained and untrained mice<sup>[4]</sup>.



All products are for RESEARCH USE ONLY. Not for diagnostic & therapeutic purposes!